Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Rapid Micro Biosystems sells machines and testing kits that help drug and medical device makers quickly check whether their products are contaminated with microbes.
Rapid Micro Biosystems makes the testing gear that pharmaceutical and medical device factories use to check whether their products are carrying invisible passengers — bacteria, mold, and other microbes. If you make a drug, a vaccine, or a medical device, you cannot release it until you have proven it is not contaminated, and that proof is one of the slowest, most paperwork-heavy parts of the whole operation.
The company's main product is a box called the Growth Direct system, which looks a bit like a very serious office printer. Factory workers put a sample into a small cartridge and load it into the machine, and the machine watches for microbes automatically and reports back digitally. The old way meant scientists peering at petri dishes day after day, writing down results on paper. Rapid Micro Biosystems sells the machines to customers, then keeps earning money on the single-use cartridges that get consumed with every test, which is the part of the business that repeats. Its customers are the big names in drugmaking and medical devices — companies like Thermo Fisher Scientific on the partner side and large pharma manufacturers who need faster release times. The pitch is simple: if a factory can find out sooner that a batch is clean, it can ship products sooner and hold less inventory. That is real money for a drugmaker, especially for biologics that can't sit around waiting.
The business is still small and still losing money, which is worth saying plainly. Revenue for 2024 was roughly $28 million, and the company has been working to grow its installed base of machines while cutting costs. Its bet is that microbial testing, one of the last corners of the factory still done with eyeballs and paper, will move into automated machines the same way so much else already has.
Saved answer · last researched 15 Nov 2026